Our Mission in Muscular Dystrophy Research
CINRG was formed in 1999 as the clinical research arm of the Duchenne Muscular Dystrophy Research Center (DMDRC) and the Research Center for Genetic Medicine at the Children’s National Medical Center (CNMC). The CINRG Coordinating Center is located in the Children’s Research Institute on the 5th floor of CNMC in Washington, DC.
Today, the CINRG program seamlessly integrates basic science projects in gene expression profiling, high throughput drug screening in the mdx mouse and drug efficacy and toxicity studies in golden retriever muscular dystrophy (GRMD) with an international, multicenter human clinical trial network.
The primary goal of the Duchenne muscular dystrophy research program is to provide a continuum of well-designed clinical trials in a geographically dispersed network of clinics so that they are available to every child with Duchenne muscular dystrophy (DMD).
The CINRG effort has blossomed into a 23-site clinical trial network in 10 countries, developing and using state-of-the-art Internet patient monitoring and close interactions with the FDA and NIH and using the Pediatric Clinical Research Center (PCRC) for patients that come to our center. CINRG currently has eight drug trials underway or completed. The muscular dystrophy clinic at CNMC has grown over 10-fold in the past 3 years as a result of the visibility of CINRG.
Current Research in Clinical Trials
Your opinion counts! Please complete the survey from National Inititives for FAMILIES WITH DUCHENNE
NIFD: NIFD
Survey National Initiative for
Families with Duchenne
CNMC0601: Prednisone High Dose vs. Daily in Duchenne Muscular Dystrophy
CNMC0302: An open-label pilot study of pentoxifylline in steroid-naive Duchenne muscular dystrophy
CNMC0705: A Double-Blinded Randomized Placebo Controlled Study of Daily Pentoxifylline as a Rescue Treatment in Duchenne Muscular Dystrophy
PITT0503: Clinical Trial of CoenzymeQ10 and Prednisone in Duchenne Muscular Dystrophy
UCD0305: Longitudinal study of the relationship between impairment, activity limitation, participation and quality of life in persons with confirmed Ducnenne muscular dystrophy